File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Levothyroxine Treatment Among Pregnant Women and Risk of Seizure in Children: A Population-Based Cohort Study

TitleLevothyroxine Treatment Among Pregnant Women and Risk of Seizure in Children: A Population-Based Cohort Study
Authors
Issue Date16-Oct-2023
PublisherSpringer
Citation
Drug Safety, 2023, v. 46, n. 11, p. 1149-1159 How to Cite?
Abstract

Introduction and Objective

The risk of seizure in offspring following prenatal exposure to levothyroxine is not well investigated. This study aimed to evaluate the association between levothyroxine treatment among pregnant women and the risk of seizure in their offspring.

Methods

This population-based cohort study included all pregnant women who delivered a live birth between January 2001 to January 2018, with a follow-up to December 2020, using data from the Hong Kong Clinical Data Analysis and Reporting System. Propensity score fine-stratification weighted hazard ratios (wHR) with 95% confidence intervals (CIs) were presented to assess the association between maternal levothyroxine use during pregnancy and seizures in children.

Results

Among 528,343 included mother–child pairs, 3044 children were prenatally exposed to levothyroxine at any time during the pregnancy period. A significantly increased risk of seizure was observed in children of the prenatally exposed group compared with the prenatally unexposed group (wHR 1.12, 95% CI 1.02–1.22). An increased risk of seizure was observed when comparing the prenatally exposed group with euthyroid mothers who had no history of thyroid-related diagnosis or prescriptions (wHR 1.12, 95% CI 1.02–1.23). However, no significant difference was observed between the prenatally exposed group and those previously exposed to levothyroxine but had stopped during pregnancy (wHR 0.97, 95% CI 0.66–1.44). No significant difference was observed in the sibling-matched analysis either (wHR 1.23, 95% CI 0.76–2.01).

Conclusion

The observed increased risk of seizure in children born from mothers exposed to levothyroxine during pregnancy might be due to residual confounding by maternal thyroid disease. The findings support the current guidelines on the safe use of levothyroxine treatment during pregnancy.


Persistent Identifierhttp://hdl.handle.net/10722/340646
ISSN
2023 Impact Factor: 4.0
2023 SCImago Journal Rankings: 1.204
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGe, Grace Mengqin-
dc.contributor.authorMan, Kenneth K C-
dc.contributor.authorCheung, Edmund C L-
dc.contributor.authorIp, Patrick-
dc.contributor.authorLeung, Wing Cheong-
dc.contributor.authorKung, Annie W C-
dc.contributor.authorCheung, Ching-Lung-
dc.contributor.authorWong, Ian C K-
dc.date.accessioned2024-03-11T10:46:07Z-
dc.date.available2024-03-11T10:46:07Z-
dc.date.issued2023-10-16-
dc.identifier.citationDrug Safety, 2023, v. 46, n. 11, p. 1149-1159-
dc.identifier.issn0114-5916-
dc.identifier.urihttp://hdl.handle.net/10722/340646-
dc.description.abstract<h3>Introduction and Objective</h3><p>The risk of seizure in offspring following prenatal exposure to levothyroxine is not well investigated. This study aimed to evaluate the association between levothyroxine treatment among pregnant women and the risk of seizure in their offspring.</p><h3>Methods</h3><p>This population-based cohort study included all pregnant women who delivered a live birth between January 2001 to January 2018, with a follow-up to December 2020, using data from the Hong Kong Clinical Data Analysis and Reporting System. Propensity score fine-stratification weighted hazard ratios (wHR) with 95% confidence intervals (CIs) were presented to assess the association between maternal levothyroxine use during pregnancy and seizures in children.</p><h3>Results</h3><p>Among 528,343 included mother–child pairs, 3044 children were prenatally exposed to levothyroxine at any time during the pregnancy period. A significantly increased risk of seizure was observed in children of the prenatally exposed group compared with the prenatally unexposed group (wHR 1.12, 95% CI 1.02–1.22). An increased risk of seizure was observed when comparing the prenatally exposed group with euthyroid mothers who had no history of thyroid-related diagnosis or prescriptions (wHR 1.12, 95% CI 1.02–1.23). However, no significant difference was observed between the prenatally exposed group and those previously exposed to levothyroxine but had stopped during pregnancy (wHR 0.97, 95% CI 0.66–1.44). No significant difference was observed in the sibling-matched analysis either (wHR 1.23, 95% CI 0.76–2.01).</p><h3>Conclusion</h3><p>The observed increased risk of seizure in children born from mothers exposed to levothyroxine during pregnancy might be due to residual confounding by maternal thyroid disease. The findings support the current guidelines on the safe use of levothyroxine treatment during pregnancy.</p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofDrug Safety-
dc.titleLevothyroxine Treatment Among Pregnant Women and Risk of Seizure in Children: A Population-Based Cohort Study-
dc.typeArticle-
dc.identifier.doi10.1007/s40264-023-01352-x-
dc.identifier.scopuseid_2-s2.0-85174307721-
dc.identifier.volume46-
dc.identifier.issue11-
dc.identifier.spage1149-
dc.identifier.epage1159-
dc.identifier.eissn1179-1942-
dc.identifier.isiWOS:001086726400001-
dc.identifier.issnl0114-5916-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats